Key Lab of Health Technology Assessment, National Health Commission (Fudan University)

WHO Collaborating Centre for Health Technology Assessment and Management

NEWSLETTER

July 2025 / Issue 2

HIGHLIGHTS

- The Team Led by Professor Chen Yingyao, Director of the Key Laboratory, Attended the 2025 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Annual Meeting
- Director of Key Laboratory Professor Chen Yingyao and Delegation Visit University of Toronto for Exchange
- Promoting Diverse Evidence Innovation, Contributing Chinese HTA Wisdom: Key Laboratory Participates in the 2025 HTAi Annual Meeting

The Team Led by Professor Chen Yingyao, Director of the Key Laboratory, Attended the 2025 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Annual Meeting

The International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 2025 Annual International Meeting was held from May 14 to 16, 2025, in Montreal, Canada. The theme of this year's conference was "Collaborating for Win-Win Outcomes to Improve Healthcare Decision-Making for Whole Populations: Expanding the Horizons of Health Economics and Outcomes Research (HEOR)". A delegation of more than ten faculty members and students from the research team of Professor Chen Yingyao, from the Key Laboratory of Health Technology Assessment of the National Health Commission (Fudan University), attended the conference, delivering one oral presentation and presenting nine poster displays.

PhD candidate Xiang Yuliang delivered an oral presentation titled "Are There Differences in Preferences for Second-Line Diabetes Medications Between Patients and Physicians? A Multicenter Discrete Choice Experiment Study" in the session "Current Trends and Advances in Health Preference Methods and Insights From Health Preference Studies". This empirical study, covering multiple centers across China, found that patients were more sensitive to financial burden and short-term glycemic control when choosing medications, whereas clinicians prioritized drug safety and long-term cardiovascular protection. Session Chair Siu Hing Lo remarked that the study provides valuable empirical evidence for understanding physician-patient decision-making disparities and offers insights for clinical practice, highlighting the need to enhance communication to better address individual patient needs while ensuring treatment efficacy.

Attendees also engaged in discussions regarding the study's findings on preference differences, their relationship with China's healthcare security system, drug selection, and reimbursement. During the session, two representatives from the UK and US also delivered thematic review reports on preference research, delving into current trends and exploring patient preferences and understanding regarding inpatient monitoring devices.

PhD candidate Li Fuming presented a poster titled "Cost-Effectiveness Analysis of Antiarrhythmic Drug Therapies for Patients with Paroxysmal or Persistent Atrial Fibrillation in China", which systematically evaluated the economic efficiency of different antiarrhythmic drugs for AF patients in China using a cost-effectiveness analysis model, providing quantitative evidence for optimizing clinical pathways. His other poster, "Cost-Effectiveness of Subcutaneous Fixed-Dose Combination of Pertuzumab and Trastuzumab for HER2-Positive Early Breast Cancer in China: A Post Hoc Analysis of the FeDeriCa Trial", focused on the economic value of a subcutaneous fixed-dose combination in breast cancer treatment, offering evidence to inform localized anti-HER2 therapy strategies in China. PhD candidate Liu Liu, through her poster "Health-Related Quality of Life Measured by the EQ-5D-5L: A Multicenter Cross-Sectional Comparison Among Clinically Diagnosed, Self-Reported Depressed, and Non-Depressed Groups", compared HRQoL differences among these groups using the EQ-5D-5L scale, revealing specific health burden manifestations across different depression cognition states.



PhD candidate Qiao Jingyi's poster, "Health-Related Quality of Life and Its Influencing Factors Among Patients with Chronic Diseases in Hainan Province, China", focused on chronic disease patients in Hainan, analyzing key social and clinical factors affecting HRQoL to support local disease burden management policies. PhD candidate Suo Yue's study, "Development of Health Technology Assessment in China: Progress and Challenges Based on a Nationwide Repeated Cross-Sectional Survey", systematically reviewed the development trajectory and challenges of HTA in China concerning policy, practice, and capacity building, providing a phased summary and outlook for constructing China's HTA system. PhD candidate Yan Juntao, in his poster "Clinical Outcome Evaluation of Portable Ultrasonic Scalpels in Urological Surgery", assessed the clinical application value of portable ultrasonic scalpels through a retrospective study, offering a comprehensive evaluation of their feasibility, safety, and promotion value. Master's candidate Tao Ying presented her study "Clinical Application of Drug-Coated Balloons for Symptomatic Intracranial Artery Stenosis: A Systematic Review and Quantitative Meta-Analysis", which investigated the clinical efficacy of DCBs via systematic review and meta-analysis. She also presented research on "Optimizing Attribute Selection for Antidepressants in Stated Preference Studies Using the Best-Worst Scaling Method", which enhanced the scientific rigor and rationality of stated preference study design by implementing BWS. PhD candidate Deng Qingwen, in his presentation "Distribution, Inequality, and Influencing Factors of Unmet Healthcare Needs Among Older Adults in China: Evidence from the National Health Service Survey", revealed the characteristics, disparities, and influencing factors of unmet healthcare needs among China's elderly population based on national survey data, providing evidence to support the precise implementation of aging health policies.



The faculty and student delegates showcased the professional capabilities and international perspectives of young Chinese scholars in pharmacoeconomics and outcomes research on the global academic stage through diverse themes, empirical data, and methodological innovation, thereby contributing wisdom and strength to promoting the high-quality development of China's healthcare system.

The International Society for Pharmacoeconomics and Outcomes Research (ISPOR), founded in 1995, is a non-profit international scientific and educational organization dedicated to pharmacoeconomics and outcomes research. The ISPOR Scientific Meetings serve as a vital platform for discussing and disseminating scientific information in health economics and outcomes research. Each year, the ISPOR annual conference attracts over 12,000 professionals from more than 120 countries and regions, aiming to advance the fields of pharmacoeconomics and health outcomes research, evaluate the clinical, economic, and other outcomes of healthcare interventions, and provide scientifically valuable reference information for policymakers.

Director of Key Laboratory Professor Chen Yingyao and Delegation Visit University of Toronto for Exchange

On May 12, 2025, a delegation of four from our laboratory, including Director of the Key Laboratory Professor Chen Yingyao, Young Associate Researcher Wei Yan, Young Associate Researcher Liu Shimeng, and Postdoctoral Researcher Yang Yi, were invited to visit the Dalla Lana School of Public Health at the University of Toronto to engage in exchanges and discussions on student education and scientific research collaboration.

Professor Adalsteinn (Steini) Brown, Dean of the School of Public Health at the University of Toronto; Professor Audrey Laporte, Director of the Institute of Health Policy, Management and Evaluation at the

School of Public Health; and Professor Wei Xiaolin, Lifetime Professor of International Health Policy at the School of Public Health, met with the delegation. At the beginning of the exchange session, Professor Chen Yingyao, Professor Audrey Laporte, and Professor Wei Xiaolin respectively conducted in-depth discussions on potential areas of collaboration.

Following the exchange activity, an academic report session was held. Professor Wei Xiaolin and Associate Professor David Naimark delivered thematic reports on "Using Implementation Science to Evaluate the Effectiveness of New Technologies" and "Dynamic Time Modeling Methods in Microsimulation Models," respectively. Professor Wei pointed out that implementation science provides a systematic framework for promoting and evaluating the effectiveness of new technologies in clinical and public health fields, emphasizing the importance of real-world data and multidimensional factors in assessing technological effectiveness. Associate Professor Naimark shared the application of dynamic time modeling in microsimulation, focusing on how event-driven simulation methods enhance the accuracy and flexibility of disease progression and health policy evaluation.

Young Associate Researchers Wei Yan and Liu Shimeng, along with Postdoctoral Researcher Yang Yi from our laboratory, presented academic reports on "Cost-Effectiveness Analysis of Non-Invasive Prenatal Testing for Down Syndrome in China," "Using Quantitative Patient Preference Data to Support Health Technology Assessment Decision-Making," and "The Application of Health Technology Assessment in Guiding the National Reimbursement Drug List," respectively. After the reports, faculty and students

engaged in lively discussions on topics related to health technology assessment, healthcare policy, pharmacoeconomics, and implementation science.

In this exchange both sides unanimously expressed their expectation to further strengthen academic exchanges and talent cultivation in future collaborations, advancing practical cooperation and common development in related fields.

Promoting Diverse Evidence Innovation, Contributing Chinese HTA Wisdom: Key Laboratory Participates in the 2025 HTAi Annual Meeting

From June 13 to 18, 2025, the Health Technology Assessment international (HTAi) 2025 Annual Meeting was grandly held in Buenos Aires, Argentina. The theme of this conference was "NextGen Evidence: Diversifying and Advancing HTA to Meet Global Demands," attracting over 700 experts and scholars from 55 countries and regions worldwide. During the conference, 3 plenary sessions, 48 parallel sessions, 32 oral presentation sessions, and multiple poster exchange sessions were held. Participants from around the world engaged in in-depth discussions and exchanges on the diversity and innovative development of

Health Technology Assessment evidence, future trends, and collectively explored new directions and challenges in the field of HTA.

During this conference, Professor Chen Yingyao, Vice Dean of the School of Public Health at Fudan University and Director of the Key Lab of Health Technology Assessment of the National Health Commission, led a team, including Associate Researcher Wei Yan, Associate Researcher Liu Shimeng, Postdoctoral Researcher Yang Yi, and others, who actively participated in multiple sessions.

Professor Chen Yingyao organized a panel discussion titled "Reassessment Of Innovative Drugs On Reimbursement List: Practices And Experiences From Multiple Countries." Postdoctoral Researcher Yang Yi served as the moderator for this session. Professor Chen Yingyao, along with Professor Tracy Merlin from Australia, Professor Li Zheng Shi from the United States, and Professor Jeonghoon Ahn from South Korea, shared in-depth content regarding the practices and experiences of innovative drug reassessment within their respective countries' reimbursement lists, and engaged in thorough discussions with the attendees.

Professor Chen Yingyao also participated as a speaker in two other panel discussions, delivering presentations titled "Applications of HTA in Benefit Plan Design in China" and "The challenge and benefits of HTA, academia and government collaborations." He detailed the application of HTA in the adjustment of China's national reimbursement drug list and the participation and collaboration of various stakeholders in the process of national innovative drug reimbursement negotiation and access. In these two panel discussions, Professor Chen Yingyao discussed the trends and challenges in the global development of HTA with experts from Argentina, India, Malaysia, Australia, and other countries.

Associate Researcher Liu Shimeng delivered an oral presentation titled "Is best-worst scaling suitable for patient preferences elicitation? An empirical comparison with discrete choice experiment." The presentation detailed the results regarding parameter estimation consistency and response decision stability between Discrete Choice Experiment and Case 2 Best-Worst Scaling, using an empirical case study of dual-drug selection for type 2 diabetes patients to introduce to peers the optimal method selection for forming patient preference evidence.

By participating in this HTAi Annual Meeting, the team from the NHC Key Laboratory of Health Technology Assessment not only showcased the latest research achievements in the field of HTA but also engaged in profound exchanges and cooperation with international peers. This further strengthened the team's influence in the global HTA field and fulfilled the conference's purpose of "expanding the global HTA network," contributing Chinese wisdom to building sustainable health service systems.

Key Lab of Health Technology Assessment,
National Health Commission (Fudan University) /
WHO Collaborating Centre for Health Technology Assessment and Management

P.O.Box 197, No 138, Yi Xue Yuan Road,
Shanghai, 200032
Tel: 86-21-33565190
Email: cwchen@shmu.edu.cn
Website: https://chta.fudan.edu.cn/

July 2025 / Issue 2